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Abstract Patients with relapsed or refractory diffuse large B
cell lymphoma (DLBCL) are treated with salvage regimens
and may be considered for high-dose chemotherapy and au-
tologous stem cell transplantation if disease is chemosensitive.
Bendamustine is active in indolent B cell lymphomas and
chronic lymphocytic leukemia but has not been extensively
studied in aggressive lymphomas. This trial examines the
combination of bendamustine and rituximab in patients
with relapsed and refractory DLBCL. Patients received
bendamustine at 90 mg/m2 (n=2) or 120 mg/m2 (n =57) on
days 1 and 2 and rituximab at 375mg/m2 on day 1 every 28 days
for up to 6 cycles. The study evaluated objective response rate
(ORR), duration of response (DOR), progression-free survival
(PFS), and treatment safety. Fifty-nine patients were treated, and
48 were evaluable for response. Median age was 74; 89 % had
stage III or IV disease, and 63 % had high revised International
Prognostic Index scores; the median number of prior therapies
was 1. Based on analysis using the intent-to-treat population, the
ORR was 45.8 % (complete response, 15.3 %; partial response,
30.5 %). The median DOR was 17.3 months, and the median
PFS was 3.6 months. Grade 3 or 4 hematological toxicities
included neutropenia (36 %), leukopenia (29 %), thrombocyto-
penia (22 %), and anemia (12 %). The combination of
bendamustine and rituximab showed modest activity in patients
with relapsed and refractory DLBCL and has an acceptable
toxicity profile.
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Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common
subtype of non-Hodgkin’s lymphoma (NHL), accounting for
approximately 30 % of all lymphoma diagnoses. It is a het-
erogeneous disorder with subtypes distinguished by various
clinical, pathologic, and molecular characteristics [1]. Since
the 1970s, the combination of cyclophosphamide, vincristine,
doxorubicin, and prednisone (CHOP) has been the standard
therapy for DLBCL in the USA [2], producing long-term 5-
year survival in 30–35% of patients with other more intensive
drug combinations producing no additional benefit [3]. In
2002, the addition of the chimeric anti-CD20 monoclonal
antibody rituximab to CHOP (R-CHOP) was shown to sig-
nificantly improve both the complete response (CR) rate and
overall survival (OS) of patients with DLBCL, with 5-year OS
of 58 % for R-CHOP versus 45 % for CHOP alone [4]. The
combination of R-CHOP has since become the most broadly
accepted treatment regimen for DLBCL.
Patients who are refractory to induction therapy or relapse
after achieving CR may be considered for salvage chemother-
apy and, if their disease is chemosensitive, for high-dose
J. L. Vacirca (*)
North Shore Hematology and Oncology Associates, 235 N Belle
Mead Road, East Setauket, NY 11733-3456, USA
e-mail: Jvacirca@yahoo.com
P. I. Acs
Florida Cancer Specialists, Gainesville, FL, USA
I. A. Tabbara
The George Washington University Medical Center, Washington,
DC, USA
P. J. Rosen
Providence Saint Joseph Medical Center, Burbank, CA, USA
P. Lee
Tower Cancer Research Foundation, Beverly Hills, CA, USA
E. Lynam
Pharmatech, Inc., Denver, CO, USA
Ann Hematol
DOI 10.1007/s00277-013-1879-x
chemotherapy and autologous stem cell transplant (ASCT).
Regimens utilized in the salvage setting, which tend to be
poorly tolerated and are frequently associated with treatment-
related complications, include combinations of ifosfamide,
carboplatin, and etoposide (ICE); dexamethasone, cytosine
arabinoside, and cisplatin (DHAP); or etoposide, methylpred-
nisolone, cytosine arabinoside, and cisplatin (ESHAP).
Rituximab is typically included as part of the salvage treatment,
despite the likelihood that most patients would have received
rituximab in prior treatment settings [5–7]. Factors that can
adversely affect the outcome after ASCT include duration of
response less than 12 months, International Prognostic Index
(IPI) greater than 1, and having received rituximab as part of
initial treatment [8]. For those patients who are not candidates
for ASCT due to advanced age, comorbidities, or chemo-
refractory disease, treatment options are limited, and prognosis
is poor.
Bendamustine, a drug developed in the former East
Germany, is an alkylating agent that appears to overcome
cross-resistance to other alkylators and contains a benzimidazole
ring, which may confer its unique properties [9]. In the USA,
bendamustine is approved for the treatment of CLL and
rituximab-refractory indolent NHL [10]. In Germany, the com-
bination of bendamustine and rituximab (BR) has been directly
compared with R-CHOP by Rummel and colleagues. The re-
sults of this trial indicate that the BR regimen produced a higher
CR rate than R-CHOP (40.1 vs. 30.8 %), along with improved
progression-free survival (69.5 vs. 31.2 months). This study was
aimed at the indolent NHL as well as mantle cell lymphoma but
did not include aggressive NHL such as DLBCL [11, 12].
Additional studies have also demonstrated activity for
bendamustine in Hodgkin’s lymphoma [13, 14], multiple
myeloma, and various solid tumors [9]. However, prospective
trials specifically investigating the efficacy of BR in patients
with DLBCL were sparse, and for that reason, we undertook a
phase II trial aimed at patients with DLBCL who are deemed
to be inappropriate candidates for intensive salvage therapies.
Patients and methods
Patient selection
Patients with histologically confirmed CD20-positive DLBCL
who relapsed or were refractory to at least one prior therapeutic
regimen were eligible for this study. Measurable disease de-
fined as at least one tumor of >1.5 cm in the longest diameter
was required. Eligible patients were required to have an Eastern
Cooperative Oncology Group (ECOG) performance status of 0
to 2; adequate hematologic, renal, and hepatic functions; and
life expectancy of at least 3 months. Autologous stem cell
transplant-eligible patients were excluded, with the exception
of those who refused ASCT. Patients with disease relapse after
prior ASCT or allogeneic stem cell transplantation were
allowed. Study patients were not candidates for high-dose ther-
apy either because of advanced age, failure of salvage therapy, or
comorbidities. Patients were naïve to bendamustine treatment.
Additional key exclusion criteria include known active
infection with human immunodeficiency virus, hepatitis B
virus, or hepatitis C virus; history of another active malignan-
cy within 1 year of study entry except for nonmelanoma skin
cancer or carcinoma in situ of the cervix or breast; grade 3 or 4
active intercurrent bacterial infection requiring treatment or
systemic fungal infection; and myocardial infarction within
6 months or New York Heart Association class III or IV heart
failure, uncontrolled angina, ventricular arrhythmia, electrocar-
diographic evidence of acute ischemia, or significant conduc-
tion system abnormalities.
Ethical oversight
All patients provided written informed consent prior to any
study-related procedures or assessments. The trial was
conducted under review of an institutional review board for
each site, in accordance with the 1964 Declaration of Helsinki
and its later amendments, US Food and Drug Administration
Good Clinical Practices, and local ethical and legal require-
ments. The study utilized a Data Monitoring Committee to
adjudicate treatment safety and efficacy data of the two-stage
design.
Treatment administration
Study patients received intravenous bendamustine and rituxi-
mab in 28-day cycle for up to 6 cycles. The dose of
bendamustine was 90 mg/m2 administered on days 1 and 2 of
each cycle for the first two patients on study. Following the US
Food and Drug Administration (FDA) approval of the indica-
tion for bendamustine in relapsed, indolent non-Hodgkin’s
lymphoma, the dosage of bendamustine was amended to
120 mg/m2 administered on days 1 and 2 of each 21-day cycle
for all other patients on study. Rituximab was administered at a
dose of 375 mg/m2 on day 1 of each cycle to all patients.
Bendamustine was provided by Cephalon, Inc. (Malvern,
PA). Rituximab was obtained through commercial sources.
Prophylactic administration of colony-stimulating factor in cy-
cle 1 was proscribed. Otherwise, the use of supportive and
prophylactic concomitant medicines followed standard prac-
tice, at investigator’s discretion.
Decisions for treatment delay and dose modification were
based on treatment emergent adverse events as graded by the
National Cancer Institute’s Common Terminology Criteria for
Adverse Events (version 3.0) and coded according to the
Medical Dictionary for Regulatory Activities (MedRA; ver-
sion 10.0) [15, 16]. In the event of grade 4 hematologic toxicity
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or clinically significant non-hematologic toxicity of ≥grade 2
on the day of intended bendamustine treatment, bendamustine
administration was delayed until recovery of non-hematologic
toxicity to ≤grade 1 or improvement of blood counts to abso-
lute neutrophil count of >1×109/L and platelets of >75×109/L.
Bendamustine could be delayed for up to 21 days andwas dose
modified in accordance with the grade and occurrence of the
adverse event. At first occurrence of a grade 4 hematologic
toxicity or clinically significant non-hematologic toxicity of
≥grade 3 at any point during a cycle, bendamustine was dose
reduced to 90 mg/m2 for all subsequent cycles. At second
occurrence of a grade 4 hematologic toxicity or clinically
significant non-hematologic toxicity of ≥grade 3 at any point
during a cycle, bendamustine was to be further dose reduced to
60 mg/m2 for all subsequent cycles. Study treatment was to be
discontinued upon the third occurrence of a grade 4 hemato-
logic toxicity or clinically significant non-hematologic toxicity
of ≥grade 3 at any point during a cycle. Treatment continued
until completion of 6 cycles of therapy, disease progression,
unacceptable toxicity, or patient withdrawal of consent.
Response assessments and criteria
After providing informed consent, study patients underwent
baseline tests which included physical examination, vital signs,
ECOG performance status, bone marrow aspirate and biopsy,
positron emission tomography and computed tomography scan,
revised IPI score documentation, electrocardiography, hematol-
ogy and serum chemistry panels, hepatitis B screening, and
pregnancy test. Response assessment was determined on study
in accordance with the revised response criteria for malignant
lymphoma [17]. Hematology and serum chemistry, adverse
events reporting, and concomitant medication documentation
were performed on days 1, 2, 8, 15, and 22 of cycles 1 to 6.
Physical examination and ECOG performance status assess-
ment were performed on day 1 of each treatment cycle. Final
safety assessment was performed 10 to 12 weeks following the
last dose of study treatment. Restaging scans and disease re-
sponse assessment were performed after every two cycles and at
3-month intervals during follow-up for up to 3 years.
Objectives and statistical design
The primary objective was to estimate the overall response rate
(ORR). Secondary objectives included the duration of response
(DOR), progression-free survival (PFS), OS, and treatment
safety. The Simon two-stage design was followed, with a
planned enrollment of at least 54 patients (a =0.1, b =0.2, P0
=50%, P1=70%) [18]. During the first stage, treatment safety
was evaluated by interim analysis (n =5). In addition, if 8 or
more of the first 15 patients (≥53.3 %) demonstrated objective
response, then the second stage could be completed, to total
sample size of at least 43 patients evaluable for ORR. The
statistical design utilized an exact two-stage binomial test
design, assuming 50 % ORR as the null hypothesis and the
alternative proportion (study ORR) of 70 % ORR, with 0.05
one-sided significance and 80 % power.
ORR was estimated as the proportion of patients who
received any dose of bendamustine, defined for this single-
arm study as the intent-to-treat (ITT) population, with the best
overall response of CR or partial response (PR). The proba-
bility of response in each category was estimated as the
proportion of patients in the ITT population attaining each
response outcome. Clopper–Pearson two-sided 95 % confi-
dence intervals were calculated. Duration of response was
measured as the time from the first documented response to
the date of disease progression. Progression-free survival was
measured as the time from the start of treatment to the date of
disease progression or death as a result of any cause. Secondary
efficacy endpoints were censored at 3 years after the start of
treatment. The time to event data was estimated by Kaplan–
Meier methods [19]. Adverse events were tabulated by patient
incidence and grade. Percentages were calculated as the pro-
portion of patients in the safety population experiencing an
adverse event. The safety population included all patients
who received at least one dose of study medication.
Results
Patient characteristics
Sixty-one patients were enrolled into the trial betweenDecember
2008 and January 2011, by 26 study centers in the Pharmatech
Research Network. All patients were determined eligible for
the study. Two patients withdrew prior to study treatment.
Fifty-nine patients were evaluated in the ITT population.
Patient characteristics are shown in Table 1. Study patients
had a median age of 74, evenly distributed for gender, and
94 % had ECOG 0 or 1. Eighty-nine percent of patients had
AnnArbor stage III or IV disease, and 63% had a poor revised
IPI risk score. Bone marrow involvement was positive in 11%
of patients. Fifty-one percent of patients had received one
prior line of therapy, 21 % had received two, 13 % had
received three, and 15 % had received more than three prior
lines of therapy. Almost all patients had received prior ritux-
imab (95 %). Five patients (8 %) had undergone prior ASCT.
Patient disposition is shown inTable 2. A total of 203 cycles
of treatment were given to 59 patients on study, with a median
of 4 cycles completed (range, 1–6 cycles). The distribution of
patients by number of cycles completed is depicted. Seventeen
patients (29 %) required reduction of bendamustine to the
90 mg/m2 dosage level, such that the mean dosage intensity
of bendamustine was 233 mg/m2 per cycle or 97 % of the
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planned dosage intensity of 240 mg/m2 per cycle. No patient
required a second bendamustine dose reduction. The dosage
of rituximab was not reduced, and 100 % of the planned
dosage of 375 mg/m2 rituximab per cycle was administered.
All patients have either completed or discontinued treatment.
Reasons for not completing the full 6 cycles of treatment
included 26 patients (44 %) with disease progression, 4 pa-
tients (8 %) withdrew consent, 4 patients (8 %) with intercur-
rent illness, and 4 patients (8 %) died on study.
Treatment safety
In the first stage of the study, five patients were assessed by a
data safety committee following completion of at least 1 cycle
of therapy. After the first two patients, the bendamustine
dose was amended to 120 mg/m2, concurrent with the US
FDA approval for indolent, relapsed non-Hodgkin’s lym-
phoma. This dose was determined by the safety committee to
have a high probability of acceptable tolerability without a
separate dose escalation study. The most common rea-
sons for bendamustine dose reduction were neutropenia and
thrombocytopenia. Other adverse events included anorexia,
Table 1 Patient demographics and clinical characteristics
Characteristic n Percent
Total enrolled 61 100
Safety population 59 97
Age, years
Median (range) 74 (25–90)
<60 9 15
≥60 52 85
Gender
Male 30 49
Female 31 51
Ann Arbor stage
I–II 6 10
III–IV 54 89
Unknown 1 1
ECOG PS
0 26 43
1 31 51
2 4 6
Bone marrow involvement
Positive 7 11
Negative 51 84
Unknown 3 5
Prior lines of therapy
1 31 51
2 13 21
3 8 13
>3 8 15
Median (range) 1 (1–9)
Prior rituximab therapy
Yes 58 95
No 3 5
Prior autologous stem cell transplant
Yes 5 8
No 56 92
RIPI risk group
Very good 0 0
Good 22 36
Poor 38 63
Unknown 1 1
Table 2 Patient disposition
Endpoint n Percent
Patients enrolled 61 100
Patients treated 59 97
Number of cycles completed 203
Mean (range) 3 (1–6)
Patients completing
1 59 29
2 50 25
3 36 18
4 29 14
5 17 8
6 12 6
Bendamustine dosage per cycle 180 mg/m2 (90 mg/m2×2)
Patients 2 3
Mean administered (range) 180 mg/m2 (180)
Bendamustine dosage per cycle 240 mg/m2 (120 mg/m2×2)
Patients 57 93
Mean administered (range) 234 mg/m2 (120–240)
Rituximab dosage 375 mg/m2
Patients 59 97
Mean administered (range) 375 mg/m2 (375)
Reasons for treatment discontinuation
in patients receiving <6 cycles
Progressive disease 26 53
Investigator decision 6 13
Patient expired 4 8
Disease related 2
Disseminated herpes zoster 1
Unknown cause 1
Intercurrent illness 4 8
Patient withdrew consent 4 8
Patient is lost to follow-up 1 2
Protocol noncompliance 1 2
Non-protocol therapy given 1 2
Irradiation of target lesion 1 2
Unknown 1 2
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dehydration, fatigue, hemoglobin, leukopenia, mucositis, shin-
gles, and weight loss. Adverse event data are presented,
according to hematologic (Table 3) and non-hematologic
(Table 4) events. Events which occurred in ≥10 % of patients
are reported for all grades combined, grade 3 events, and grade 4
events. The most common hematologic adverse event reported
in the study was neutropenia, thrombocytopenia, and anemia,
each occurring in 44 % of patients. Grade 4 adverse events
included febrile neutropenia in four patients (7 %), thrombocy-
topenia in three patients (5 %), and leukopenia in one patient
(2 %). Grade 3 adverse events included neutropenia in 17
patients (29 %), thrombocytopenia in 10 patients (17 %), leuko-
penia in 13 patient (22%), and anemia in 7 patients (12%). Four
deaths occurred on during the study, including two patients who
died from disease-related complications, one patient from dis-
seminated herpes zoster, and one patient of unknown cause.
Efficacy
In stage 1 of the study, 9 of the first 15 patients treated (60 %)
achieved an objective response; therefore, the study was
allowed to complete the enrollment. The final study ORR
was 45.8 % (27/59 patients; 95 % confidence interval (CI),
41–70 %), including 15.3 % CR and 30.5 % PR, shown in
Table 5. Stable disease was reported in 18.6 % percent of
patients, while 16.9 % progressed on treatment or withdrew
prior to evaluation. While the observed ORR is clinically
significant, it did not meet the statistical endpoint of 70 %
response rate for BR in this treatment population.
Kaplan–Meier regression of event-free outcomes and DOR
are depicted in Fig. 1. Median DOR among 27 patients with an
objective response was 17.3 months (Fig. 1a; 95 % CI,
4.2 months; upper limit not reached). Response was maintained
for 15 patients at the data censor date. Median PFS was
3.6 months (Fig. 1b; 95 % CI, 2.7–7.2 months). Eighteen
patients remained progression free at the data censor date.
Patient overall survival was evaluated for the 3-year period
beginning with the initiation of study treatment. Due to a high
number of censored data, as patients withdrew from study
follow-up, the median OS was not reached (data not shown).
Discussion
The treatment of DLBCL changed dramatically with the land-
mark GELA trial which demonstrated dramatic response and
survival advantages with the addition of rituximab to the
established standard, CHOP. Nevertheless, a significant pro-
portion of patients remains either refractory to or relapses after
R-CHOP therapy. Depending on the stage of the disease, the
clinical IPI scores, and biologic characteristics, up to 40 % of
Table 3 Hematologic adverse events occurring in DLBCL patients
receiving bendamustine and rituximab
Event All grades Grade 3 Grade 4
n Percent N Percent n Percent
Neutropenia 26 44 17 29 4 7
Leukopenia 20 34 13 22 1 2
Thrombocytopenia 26 44 10 17 3 5
Anemia 26 44 7 12 0 0
Severity was determined from post-baseline laboratory results using the
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0, and MedRA
Table 4 Non-hematologic adverse events occurring in DLBCL patients
receiving bendamustine and rituximab. Censored at 10 %
Event All grades Grade 3 Grade 4
n Percent N Percent n Percent
Nausea 24 41 1 2 1 2
Fatigue 21 36 2 3 0 0
Diarrhea 18 30 2 3 0 0
Fever 17 29 1 2 1 2
Anorexia 14 24 3 5 0 0
Constipation 13 22 0 0 0 0
Cough 11 19 1 2 0 0
Weight loss 11 19 1 2 0 0
Vomiting 10 17 1 2 1 2
Dizziness 9 15 2 3 0 0
Abdominal pain 8 14 3 5 0 0
Limb edema 8 14 1 2 0 0
Pain 8 14 0 0 0 0
Back pain 7 12 1 2 0 0
Chills 6 10 0 0 0 0
Dehydration 6 10 2 3 0 0
Dyspnea 6 10 3 5 0 0
Headache 6 10 1 2 0 0
Hypotension 6 10 0 0 1 2
Severity was determined from post-baseline laboratory results using the
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0, and MedRA
Table 5 Treatment response
Response category n Percent (n =59)
ORR 27 45.8
CR 9 15.3
PR 18 30.5
SD 11 18.6
PD 10 16.9
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patients may not be cured. Certain subtypes of DLBCL, such
as the so-called double-hit lymphomas, have a particularly
ominous prognosis [20]. The standard of care for
chemosensitive, medically fit relapsed or refractory patients
has been ASCT. Paradoxically, in the rituximab era, the out-
come following ASCT has worsened. Gisselbrecht has de-
fined adverse prognostic factors for survival following ASCT
such as prior rituximab (which includes virtually all patients),
short duration of response (<12 months), and high IPI score at
relapse (>1) [8]. Taken together, the overall cure rate follow-
ing ASCT is probably no greater than 20 % [8, 21]. New
agents whichmay have impact on the management of DLBCL
include the immunoconjugates [22], B cell receptor [23] ki-
nase inhibitors such as agents inhibiting PI3 kinase [24],
Bruton’s tyrosine kinase [25], splenic tyrosine kinase [26],
and immunomodulators such as lenalidomide [27].
In our study, we examined a group of patients who had a
median age of 74 years and who were determined by their
physicians not to be good candidates for ASCTor aggressive
salvage regimens. Bendamustine, a novel alkylating agent
that demonstrates a lack of cross-resistance with standard
alkylators, has shown a significant activity in a variety of
lymphoproliferative diseases, including chronic lymphocytic
leukemia and indolent lymphomas. More recently, activity
has been demonstrated in multiple myeloma and Hodgkin’s
lymphoma. Aggressive lymphomas such as DLBCL have
been less extensively studied. In our trial, the combination of
bendamustine and rituximab produced an ORR of 45.8 %
with complete responses in 15.3 % of patients. The median
duration of response was 17.3 months with an intention-to-
treat progression-free survival of 3.6 months. While these
results are inferior to the results anticipated with more aggres-
sive salvage regimens such as R-ESHAP and R-ICE, the
intent-to-treat population of our study was patients who were
poor candidates by age and medical criteria for such aggres-
sive therapy. A review of previous experiences in aggressive
lymphomas using bendamustine includes a small number of
manuscripts. Weidmann et al. reported an ORR of 44 %
utilizing single-agent bendamustine in a study of 21 patients
[28]. Rigacci et al. published a small study experience includ-
ing bendamustine with or without rituximab in a variety of
NHL subtypes [29]. In 34 patients with DLBCL, the ORRwas
33 % with 12 % CR, which is similar to our experience. In a
small study reported as a letter to the editor, Walter et al. noted
a 57 % ORR (CR 29 %) in eight relapsed patients, while no
patient with refractory disease demonstrated a response [30].
Horn et al. treated a total of 20 patients with so-called aggres-
sive lymphoma, 75 % of whom had DLBCL [31]. The ORR
in that trial was 55%. In that study of frail and elderly patients,
both previously untreated and relapsed patients were included.
Finally, a very recent phase II trial in DLBCL reported a
higher response rate of 63 % (CR 37 %), using 120 mg/m2
bendamustine with rituximab, which is the most favorable
experience yet with this combination [32]. Other alternatives
to be considered in the relapsed/refractory population of
DLBCL include the gemcitabine–oxaliplatin combination
[33]. The results of this combination may be somewhat better
than reported for BR, but it is premature to compare regimens
in the phase II setting.
Despite the fact that most of our patients received a dose of
120 mg/m2 bendamustine, higher than the usual dose of 90 mg/
m2 used in rituximab combinations, the regimen was reason-
ably well tolerated, although a dose reduction was employed in
a third of our patients. Only 7 % of patients developed febrile
neutropenia. In summary, the combination of bendamustine
and rituximab showed modest activity in DLBCL; in an ad-
verse population of patients not felt suitable for transplanta-
tion, only 5 of the 61 patients enrolled had undergone prior
ASCT. The role of bendamustine in treating both newly diag-
nosed and progressive DLBCL bears further study. Ongoing
trials are evaluating bendamustine in combination with ritux-
imab, ofatumumab, or rituximab with lenalidomide in
untreated patients who are not candidates for R-CHOP. A
recent experience including treatment-naïve patients over age
80 showed encouraging results [31]. Further combinations
utilizing bendamustine in the salvage setting with additional
a
b
Fig. 1 Kaplan–Meier time to event curves. Vertical axis represents the
percentage of patients. Horizontal axis depicts time in months. a Dura-
tion of response (median=17.3 months). b Progression-free survival
(median=3.6 months)
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drugs, as well as pre-transplant conditioning regimens, are also
being evaluated in clinical trials.
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